NEW YORK, March 20 – Beckman Coulter announced Tuesday a reorganization plan, including the establishment of three new biomedical testing divisions.
The Fullerton, Calif.-based company said its biomedical testing operations would now be organized into the life science research division, the specialty testing division, and the clinical diagnostics division.
"Several factors -- including record sales and profits in 2000, a broad array of products spanning the biomedical testing continuum and our global presence -- combine to make this an ideal time for Beckman Coulter to pursue new opportunities," John Wareham, Beckman Coulter’s CEO, said in a statement. "Because we believe our growth is tied to the resources we allocate to develop these opportunities, Beckman Coulter is putting the framework in place for a new organization structure that will take shape over the remainder of the year."
George Bers, who recently joined Beckman as vice president of bioresearch will head the life science research division; Edgar Vivanco, previously senior vice president of Beckman’s diagnostic development, corporate manufacturing and quality department, will lead the specialty testing division; and Albert Zieglera, formerly senior vice president of the company’s diagnostics commercial operations, will be in charge of diagnostic commercial operations.
Beckman Coulter provides instruments for everything from complex DNA sequencing to simple, one-use diagnostic screening kits.
The company said it expects to see growth in all three biomedical divisions, noting that the reorganization would better enable the company to oversee the allocation of resources.